{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-010101","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2025-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.206022+00:00","generated_at":"2026-05-16T12:57:39.963278+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeOnc reports updated NEO100 data: 24% radiographic remission, 44% PFS-6 in recurrent IDH1-mutant astrocytoma","bullets":["6 of 25 patients (24%) achieved radiographic remission vs <8% historical salvage therapies.","44% achieved 6-month progression-free survival (PFS-6), exceeding historical 21-31% benchmarks.","9 of 25 patients (36%) remain alive ≥18 months post NEO100 initiation; no significant toxicity seen.","All patients had recurrent WHO Grade III/IV IDH1-mutant astrocytoma; data from Phase 1/2a and compassionate use."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-010101","json":"https://secwatch.observer/filing/0001829126-25-010101.json","markdown":"https://secwatch.observer/filing/0001829126-25-010101.md","text":"https://secwatch.observer/filing/0001829126-25-010101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912625010101/0001829126-25-010101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912625010101/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:57:39.963278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}